A Phase I/IIa trial of HA-Irinotecan, a formulation of hyaluronic acid and irinotecan, in the treatment of extensive stage small cell lung cancer and its effect on tumour stem cells.

Southern Health0 个研究点目标入组 40 人开始时间: 2011年5月20日最近更新: 2020年1月13日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 40

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Randomised controlled trial
主要目的: Treatment
盲法: Blinded (masking used)

入排标准

年龄范围: 18 Years 至 90 Years（—）
性别: All

入选标准

•Patients must fulfill all of the following criteria to be eligible for admission to the study:
•18 years of age and older
•Male or female
•Histologically or cytologically confirmed small cell lung cancer, that is defined as a previously untreated metastatic or extensive disease:
•Malignant pleural effusion or multifocal lung disease is considered metastatic or extensive disease.
•Prior radiotherapy allowed.
•Measurable disease, defined as 1 unidimensionally measurable lesion equal to1 cm by physical examination or radiographic techniques
•Known brain metastases allowed.
•Eastern Cooperative Oncology Group(ECOG) performance status 0-2
•Life expectancy greater than 3 months
•Haematology done within 7 days prior to first treatment and with initial values within the ranges specified below (transfusions are appropriate to bring patients into the appropriate ranges, however, there must be no evidence of active bleeding):
•White Blood cell count greater than 3,000/mm^3
•Absolute neutrophil count greater than 1,500/mm^3
•Platelet count greater than 100,000/mm^3
•Hemoglobin greater than 9.0 g/dL
•Biochemistry done within 7 days prior to first treatment and with initial values within the ranges specified below:
•Bilirubin greater than1.5 mg/dL
•Alanine transaminase greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present)
•Not pregnant or nursing
•Negative pregnancy test
•Women of child-bearing potential (WOCBP) and male partners of WOCBP must agree to use adequate contraception prior to study entry, throughout the study and for a period of 3 months after cessation of protocol therapy. WOCBP include any women who have experienced menarche and who have not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or are not postmenopausal (defined as amenorrhoea > 12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level greater than 35 mIU/mL). Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or who are practicing abstinence or whose partner is sterile (eg., vasectomized) should be considered to be of child-bearing potential.
•No medical disease that, in the opinion of the investigator, would preclude study treatment
•Imaging investigations including at least chest computed tomography (CT) or Magnetic Resonane Imaging (MRI) scan and CT or MRI of abdomen/pelvis with other scans as necessary to document all sites of disease, done within 28 days prior to treatment. Contrast enhancement should be used if no contraindication. The same imaging method should be used for the patient throughout the entire study (e.g. if a patient starts with CT scans all subsequent imaging should be with CT scans).
•At least 10 days since prior radiotherapy (including brain)
•At least 2 weeks since prior and no concurrent anticonvulsants
•No concurrent radiotherapy.
•The patient must sign the consent form prior to registration.
•The baseline assessment must be completed within 7 days prior to first treatment.
•Patients must be accessible for treatment and follow-up. Investigators must assure themselves that patients registered on this trial will be available for complete documentation of the treatment, toxicity, and foll

排除标准

•Patients who fulfill any of the following criteria are not eligible for admission to the study:
•Previous exposure to any chemotherapy for small cell lung cancer
•Bilirubin greater than 1.5 mg/dL
•ECOG greater than 2
•Active inflammatory bowel disease or any chronic diarrhoea grade 2.
•Bulky disease (>50% hepatic involvement, >25% lung involvement, or abdominal mass 10 cm) due to an increased risk of toxicity.
•Radiotherapy within the preceding 4 weeks, unless to a single bone site.
•Documented unsuitability for irinotecan includes known hypersensitivity to a camptothecin drug, abnormal glucuronidation of bilirubin or Gilbert’s syndrome.
•Patients receiving treatment with phenobarbitone, St John’s Wort, phenytoin or valproate.
•Partial or complete bowel obstruction.
•Concomitant active infection.
•Currently active second malignancy, other than non-melanoma skin cancers.
•Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with interpretation of study results.
•Pregnant or lactating women or women of childbearing potential not using adequate contraception.
•Any active pathological condition that would render the protocol treatment dangerous or impair the ability of the patient to receive protocol therapy.
•Any condition (e.g., psychological, geographical) that does not permit compliance with the protocol

研究者

发起方

Southern Health

相似试验

已完成

1 期

Phase I-II clinical trial of irinotecan hydrochloride (CPT-11) for refractory pediatric solid tumors

JPRN-C000000314CPT-PED-05 administrative office30

已完成

1 期

Phase I-II clinical trial of irinotecan hydrochloride (CPT-11) for refractory pediatric solid tumors

JPRN-jRCT1091220004CPT-PED-05 administrative office30

招募中

2 期

Randomised Phase II trial of irinotecan with hyaluronic acid (HyCAMP) versus irinotecan as treatment for patients with metastatic colorectal cancer who have failed 5-FU based chemotherapyMetastatic colorectal cancerCancer - Bowel - Back passage (rectum) or large bowel (colon)

ACTRN12605000119695Meditech Research Limited86

已完成

1 期

Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer

NCT03290937M.D. Anderson Cancer Center34

进行中（未招募）

不适用

A clinical trial to compare tolerabilty and efficiacy (how well the drug works) of following treatments:Blocking liver arteries (chemoembolisation) by beads loaded with irinotecan (chemotherapeutic) and intravenous administration of cetuximab (chemotherapeutic) compared to administration of intravenous cetuximab and irinotecan in patients with k-ras (gene) wild-type tumors.Patients with unresectable liver metastases of colorectal cancer who previously failed pretreatment with 5FU/oxaliplatin and/or 5FU/irinotecan (2nd- or 3rd-line).MedDRA version: 14.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2009-014728-44-DEMartin Luther Universität Halle-Wittenberg80